Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

BACKGROUND: Vatreptacog alfa, a recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions and 99% identity to native FVIIa, was developed to improve the treatment of hemophilic patients with inhibitors. OBJECTIVES: To confirm the safety and assess the efficacy of vatreptacog alfa i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lentz, S R, Ehrenforth, S, Abdul Karim, F, Matsushita, T, Weldingh, K N, Windyga, J, Mahlangu, J N, For the Adept™2 Investigators
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Clinical Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238784/
https://www.ncbi.nlm.nih.gov/pubmed/24931322
http://dx.doi.org/10.1111/jth.12634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238784/
https://www.ncbi.nlm.nih.gov/pubmed/24931322
http://dx.doi.org/10.1111/jth.12634

Ejemplares similares